A phase I/II trial of tinzaparin (Innohep) [tinzaparin sodium], a low molecular weight heparin (LMWH) for treatment of advanced renal cell carcinoma.

Trial Profile

A phase I/II trial of tinzaparin (Innohep) [tinzaparin sodium], a low molecular weight heparin (LMWH) for treatment of advanced renal cell carcinoma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Tinzaparin sodium (Primary)
  • Indications Renal cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jun 2007 Status changed from recruiting to in progress.
    • 06 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top